🇺🇸 FDA
Patent

US 10301365

Met e 1 tropomyosin variants for use in allergen-specific immunotherapy

granted A61KA61K38/00A61K38/1709

Quick answer

US patent 10301365 (Met e 1 tropomyosin variants for use in allergen-specific immunotherapy) held by The Regents of the University of California expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/00, A61K38/1709, A61K9/0019, A61K9/0053